Details of the Drug

General Information of Drug (ID: DMX9YLR)

Drug Name
Pridopidine
Synonyms
PRIDOPIDINE; 346688-38-8; 4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine; 4-(3-(Methylsulfonyl)phenyl)-1-propylpiperidine; ACR-16; UNII-HD4TW8S2VK; ACR16; ACR 16; HD4TW8S2VK; CHEMBL596802; FR310826; Pridopidine [USAN:INN]; Pridopidine (USAN/INN); 4-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine; SCHEMBL166748; CTK4H2809; DTXSID90188225; ASP 2314; ZINC22063703; BDBM50308028; AKOS015891431; DB11947; NCGC00386586-01; HY-10684; AS-50146; AJ-80925; FR 310826; DB-014417; AX8258340; CS-0002733; FT-0672149; Huntexil; Pridopidine hydrochloride; ASP-2314; Dopamine modulator (Huntingtons disease), Carlsson Research; Dopamine modulator (Huntingtons disease), NeuroSearch; Dopamine modulator (schizophrenia), Astellas; Dopamine modulator (schizophrenia), Fujisawa; Dopamine modulator (neurological disorders), Merck & Co
Indication
Disease Entry ICD 11 Status REF
Huntington disease 8A01.10 Phase 3 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 281.4
Topological Polar Surface Area (xlogp) 2.6
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
Chemical Identifiers
Formula
C15H23NO2S
IUPAC Name
4-(3-methylsulfonylphenyl)-1-propylpiperidine
Canonical SMILES
CCCN1CCC(CC1)C2=CC(=CC=C2)S(=O)(=O)C
InChI
InChI=1S/C15H23NO2S/c1-3-9-16-10-7-13(8-11-16)14-5-4-6-15(12-14)19(2,17)18/h4-6,12-13H,3,7-11H2,1-2H3
InChIKey
YGKUEOZJFIXDGI-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
9795739
CAS Number
346688-38-8
DrugBank ID
DB11947
TTD ID
D0F4SY
VARIDT ID
DR00875

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Modulator [2], [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Huntington disease
ICD Disease Classification 8A01.10
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT00665223) A Study of Treatment With ACR16 in Patients With Huntington's Disease. U.S. National Institutes of Health.
2 Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease. Clin Neuropharmacol. 2010 Sep-Oct;33(5):260-4.
3 Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabi... J Med Chem. 2010 Mar 25;53(6):2510-20.
4 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
5 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
6 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
7 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
8 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
10 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
11 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
12 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
13 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.